Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, strengthening Co-Dx's intellectual property portfolio surrounding its novel Co-Dx PCR platform*. Co-Diagnostics, Inc., a molecular diagnostics company, has received a patent from the Australian Patent Office for its new point-of-care testing platform, Co-Dx. The patent is the first granted for the platform and provides broad protection in Australia for the Company's proprietary system and methods used for nucleic acid detection and analysis. The claims specifically cover the design and operation of the Co-dx PCR Pro™ instrument and test cups. This patent represents a significant milestone in securing global protection for Co-Douglas' technology. The Co-Darche platform is designed to deliver gold-standard PCR accuracy in a compact device suitable for decentralized testing environments.
Опубликовано : 6 месяцев назад от PR Newswire в Finance
The Australian patent represents the first patent granted for the Company's new point-of-care testing platform
SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-D... [2542 symbols]
Темы: Australia